|Home | About | Journals | Submit | Contact Us | Français|
The purpose of the research was to explore the therapeutic action of simvastatin-loaded poly(ethylene glycol)-b-poly(gamma-benzyl l-glutamate) (PEG-b-PBLG50) on intestinal ischemia/reperfusion injury (II/RI) through downregulating bone morphogenetic protein 4 (BMP4)/cyclooxygenase-2 (COX-2) pathway as compared to free simvastatin (Sim). Sprague Dawley rats were preconditioned with 20 mg/kg Sim or simvastatin/PEG-b-PBLG50 (Sim/P) compounds, and then subjected to 45 min of ischemia and 1 h of reperfusion. The blood and small intestines were collected, serum levels of interleukin-4 (IL-4), interleukin-6 (IL-6), interleukin-10 (IL-10), tumor necrosis factor-α, and nitric oxide (NO) were checked, and the dry/wet intestine ratios, superoxide dismutase activity, myeloperoxidase content, reactive oxygen species, endothelial nitric oxide synthase, protein 47 kDa phagocyte oxidase (p47phox), BMP4, COX-2, and p38 mitogen-activated protein kinase (p38MAPK) expressions were measured in intestinal tissues. Both Sim and Sim/P pretreatment reduced intestinal oxidative damnification, restricted inflammatory harm, and downregulated the BMP4 and COX-2 expressions as compared to II/RI groups, while Sim/P remarkably improved this effect.
Intestinal ischemia/reperfusion injury (II/RI) is a major pathophysiological phenomenon and a potentially life-threatening problem in clinical medicine.1,2 The mortality rates from II/RI are very high and reach more than 60% and it often requires clinical operation to cut off the necrotic intestinal segment.3,4 It causes the tissue injury through inadequate blood and oxygen supply relative to cellular energy stores exhaustion, tissue metabolic disorder, and toxic metabolites accumulation in intestinal ischemia phase and leads to reactive oxygen species (ROS), inflammatory factors, calcium overload, and so on, mediating the further damage of intestine in reperfusion phase.5 It is well known that oxygen supply reestablishment results in ROS production, causing lipid oxidation reaction in cell membranes,6 and blood supply reestablishment leads to production of a lot of inflammatory factors to aggravate tissue injury and intestinal barrier dysfunction, and toxic metabolite products enter the systemic blood circulation and threaten life.7
ROS is engendered on intestinal ischemia/reperfusion (I/R), and is one of the major reasons of intestinal damage.8 Previous studies have showed that nicotinamide adenine dinucleotide phosphate (NADPH) oxidase is the key enzyme that is involved in ROS production.9 NADPH oxidase is composed of at least five protein components and three cytosolic components (including p47phox).10 p47phox is the subunit mainly responsible for transporting the cytosolic complex from the cytosol to the membrane in oxidase activation and impels ROS production.10 Many exogenous antioxidants (including superoxide dismutase [SOD]) aimed to reduce ROS damage have been studied in the treatment of I/R-induced intestinal injury.11 More and more evidence has demonstrated that stimulation of endogenous antioxidant systems may be an important tactic for achieving intestinal protection on I/R injury.11
The disorder of proinflammatory and anti-inflammatory factors boosts II/RI.1 Proinflammatory factors including interleukin-6 (IL-6) and tumor necrosis factor (TNF-α) generated largely, and anti-inflammatory factors including interleukin-4 (IL-4) and interleukin-10 (IL-10) engendering insufficiently via damaged intestines and blood have been involved as the chief contributor of II/RI.12,13
Bone morphogenetic protein 4 (BMP4) is one of the BMP families (including BMP2-BMP9).14 Previous studies have affirmed that BMP4 has a role with BMP receptors involving type I and type II15 and then adjusts physiopathologic process of bodies.16–18 Some documents have shown that BMP4 exacerbates exaggeratin cardiac I/R injury.19 In addition, BMP4 is a proinflammatory gene that induces endothelium dysfunction, mediating abnormal expression of endothelial nitric oxide synthase (eNOS) and leads to impairment of vascular relaxation,20 and that activates NADPH oxidase to induce ROS production and then improves the expression of cyclooxygenase-2 (COX-2) through p38 mitogen-activated protein kinase (p38MAPK).21 COX-2 promotes vasopermeability and aggravates tissues’ damage.21
Many documents have attested that simvastatin (Sim) can protect the small intestine against (I/R) damnification.22–24 In the present study, we try to explore the protective effect of Sim on II/RI. As is well known, the in vivo solubility of Sim is very low and circulation time is very short.25–27 Here, a poly(ethylene glycol)-b-poly(gamma-benzyl l-glutamate) (PEG-b-PBLG50; P) block multipolymer (framework depicted in Figure 1) as a latent Sim nanoparticle is reported. The block multipolymer is synthesized through the ring-opening polymerization of BLG-N-carboxyanhydride (NCA) with PEG-NH2 as the macroinitiator. The P and Sim integrate into a compound through hydrophobic functions. The encapsulated Sim shows stable release, which can promote the research on the protective action of Sim. Sim loading and in vitro release are confirmed. In vivo research is conducted through the hypodermic injection of the Sim/P compound to II/RI in rats, followed by the determination of serum IL-4, IL-6, IL-10, TNF-α, and nitric oxide (NO), measurements of SOD activity and methane dicarboxy-lic aldehyde (MDA) level in small intestinal tissues, and finally the ROS, eNOS, protein 47 kDa phagocyte oxidase (p47phox), BMP4, COX-2, and p38MAPK expressions in small intestinal tissues.
PEG-NH2 (molecular weight, 5 kDa), dimethyl formamide (DMF), and BLG were bought from Aladdin (Shanghai, China); regenerative fiber dialysis bag (molecular weight cut off [MWCO], 3.5 kDa, 7 kDa) was bought from Union Cardibide Company (Danbury, CT, USA); simvastatin was bought from Shangyu Hangzhou Jing Xin Pharmaceutical Co., Ltd; Hela cells were bought from Shanghai Forte Cheng Biological Technology Co., Ltd; other reagents were bought from Sigma.
PEG-b-PBLG50 was synthesized by following way: The ring-opening polymerization of BLG-N-carboxyanhydride with PEG-NH2 as the macroinitiator obtained PEG-b-PBLG, as described in Figure 2. BLG-NCA was synthesized and characterized by a previously published method.28 The right amount of PEG-NH2 in 10 mL of DMF was mixed with a quantity of BLG-NCA/DMF fluid (0.1 g/mL) by vacuumization and nitrogen protection. The corresponsive compounds were stirred at 40°C for 3 days and dialyzed for 3 days using dialysis tubing (MWCO, 7 kDa). The PEG-b-PBLG polymers were gained by freeze drying, the degree of polymerization of PBLG was 50, and they were characterized by 1H-nuclear magnetic resonance, gel permeation chromatogram, and Fourier transform infrared spectroscopy.
The detailed method for the cytotoxicity evaluation of block copolymer PEG-b-PBLG50 is referred to the technology and method specified in our previous article.29
To assess the loading of simvastatin by PEG-b-PBLG50, a certain amount of simvastatin (5 mg/mL) in phosphate buffered solution (PBS) (pH =7.2, 0.01 mmol/L; including 2% dimethyl sulfoxide) was mixed with PEG-b-PBLG50 in a PB solution. And then the mixed solutions were transferred to a dialysis bag (MWCO, 7 kDa) and dialyzed. When the sunk polymer in the test was wholly removed, the polymer-loaded simvastatin was measured through high-performance liquid chromatography (HPLC) and transmission electron microscopy (TEM).
Simvastatin releases from the PEG-b-PBLG50 were detected by dialysis (MWCO, 7 kDa) at room temperature with 5 mL of simvastatin/PEG-b-PBLG50 compound against 60 mL of 0.02 mol/L PB (pH 7.4). At 0.02-, 0.04-, 0.08-, 0.17-, 0.33-, 0.42-, 0.5-, 0.67-, 0.75-, 1-, 1.5-, 1.67-, 1.75-, 2-, 3-, and 4-day time interval, a certain amount of release mediums were retrieved and supplemented with a proper amount of fresh release mediums. The quantity of released simvastatin remaining in the dialysis bag was measured through HPLC. The free simvastatin releases in the absence of polymeric compound were also executed as a control.
The Sprague Dawley (SD) rats were administrated a dose of 20 mg/kg simvastatin (Sim) or simvastatin/PEG-b-PBLG50 (Sim/P) by abdominal subcutaneous injection. Blood (0.2 mL) was extracted to put into heparinized tubes at specified time intervals. Blood was separated immediately by centrifugation (12,000× g for 15 min at 4°C) and stored under −80°C for the following analyses. The concentration of Sim and Sim/P in rat blood was measured by liquid chromatography tandem mass spectrometry following the previous methods.30
The SD rats were administrated a dose of 20 mg/kg Sim or Sim/P by abdominal subcutaneous injection. The different tissues were extracted and put into test tubes, where the miscible liquids containing 0.2 mL 60% perchloric acid and 0.2 mL 30% hydrogen peroxide were added. The samples were put into an 80°C water bath for 40–60 min and then the color of the samples became faint yellow. 0.2 mL of the tissues liquids were extracted to add 1 mL of scintillation solution and 3 mL of absolute ethyl alcohol, then the radioactivity of different tissues were checked by TRI-CARB2900 TR liquid scintillation counter (PACKARB) following previous methods.31
SD rats (180–220 g) were accommodated by the Animal Research Center of Jiaxing University Medical College, Jiaxing, People’s Republic of China. All the procedures and care administered to the animals had been approved by the Institutional Ethics Committee of Jiaxing University Medical College. The investigation conformed to the guide for the care and use of laboratory animals published by the US National Institutes of Health (NIH Publication updated in 2011). In the research, 40 SD rats were assigned to four groups (each group including 10 rats): 1) Sham group; 2) I/R group: SD rats were anesthetized with 1% pentobarbital sodium (50 mg/kg) through intraperitoneal injection. The abdomina were opened and the arteriae mesenterica superior were separated to be clamped for 45 min by a small vessel clip, followed by 1 h of reperfusion; 3) simvastatin (Sim) group: Sim was administrated once a day (20 mg/kg) through abdominal subcutaneous injection, for 8 days prior to the I/R procedures; 4) simvastatin/PEG-b-PBLG50 (Sim/P) group: Sim/P was administrated once every 4 days (20 mg/kg) through abdominal subcutaneous injection, for 8 days prior to the I/R procedures. The blood was collected from the abdominal aorta and centrifuged under 3,600× g for 20 min to gain the sera. A segment of small intestine of SD rats was removed to weigh the wet intestine and it was baked for 48 h under 80°C to weigh the dry intestine. A segment of small intestine was cut off right away and stored at −80°C until analysis.
SOD activity and MDA content of intestinal tissues were checked using the previous methods.32 The intestines were collected after reperfusion for 1 h and the blood was purged drastically, homogenized (100 mg), and centrifuged at 3,600× g for 20 min to gain the liquid supernatant. SOD activity and MDA level were checked through xanthine oxidase and thiobarbituric acid method.30 The absorbances were checked at 550 and 532 nm, respectively. Lipid peroxide contents are shown by “U” of SOD/mg pro and “nmol” of MDA/mg pro in tissues.
The methods have been described previously.33 The blood was collected after reperfusion for 1 h and centrifuged at 3,600× g for 20 min to gain the liquid supernatant. The NO2−/NO3− content was measured by nitrate reductase and absorption photometry. The absorbances were checked at 550 nm. The content of NO2−/NO3− is shown in “μmol” of NO2−/NO3−/L serum.
The method was depicted mainly through previous reports.12,13 The sampling process was the same as above. The IL-4, IL-6, IL-10, and TNF-α contents were measured by double anti-sandwich ABC-ELISA method. The absorbances were checked at 450 and 492 nm, respectively. The levels of IL-4, IL-6, IL-10, and TNF-α were expressed in “ng” of IL-4, IL-6, IL-10, and TNF-α/L serum.
Previous methods have been referred to here.34–37 After 1 h of reperfusion, SD rats were anesthetized with 1% pentobarbital sodium (50 mg/kg), and CM-H2DCFDA (100 μg) was injected into the intestinal circulation. After CM-H2DCFDA injection, the small intestine was harvested for 45 min and dipped in 4% paraformaldehyde for about 24 h. After treatment with 20% sucrose for about 12 h, the small intestine was immediately frozen in liquid nitrogen. Cryostat sections were cut at −20°C and the sections were placed on Star-Frost adhesive slides and air-dried for about 3 min. Parts were washed in PBS and stained with DAPI for fluorescence microscopy analysis in ROS qualitative evaluation. ROS quantitative evaluation in isolated mitochondria was performed using the amplex red H2O2/peroxidase assay kit using a spectrofluorometer and emission wavelengths of 544 and 590 nm, respectively.
Previous methods have been referred to here.21,38–40 Briefly, small intestinal tissues were homogenized in protein lysate buffer. The homogenate was resolved on polyacrylamide sodium dodecyl sulfate gels, and electrophoretically transferred to polyvinylidene difluoride membranes. The membrane was blocked with 3% bovine serum albumin, and incubated with primary antibodies (Abs) against active eNOS, p47phox, p38MAPK, BMP4, COX-2, and subsequently with alkaline phosphatase-conjugated secondary Abs. It was developed via 5-b-romo-4-chloro-3-indolyl phosphate/nitroblue tetrazolium. Blot was stained through anti-β-actin Ab, and the content of protein was normalized with respect to β-actin and density.
Previous methods have been referred to here.41–43 Sections with a thickness of 5 μm were obtained from the small intestine parts and mounted on poly-l-lysine-coated slides. The parts were immersed in 0.3% H2O2 for 20 min and washed with PBS. The parts were then incubated in rabbit anti-COX-2, anti-BMP4, and anti-p38MAPK polyclonal antiserum (Abcam, UK) for 1 h (1:100 dilution). After the primary incubation and three rinses in PBS, parts were incubated in biotinylated goat anti-rabbit IgG (Invitrogen, CA, USA) for 15 min (1:2,000 dilution). Following the incubation in substrate chromagen solution for 15 min, all parts were washed in PBS and distilled water, mounted in glycerol, and checked later under the microscope. The small intestinal parts stained positively for COX-2, BMP4, and p38MAPK were evaluated and compared among groups.
All experiments were repeated in triplicate. All the data were depicted as mean values ± standard deviation. An analysis of variance test and a Student’s t-test usually assessed statistical significance. A value of <0.01 (P<0.01) was regarded as statistically significant.
The PEG-b-PBLG was made up of a PEG block and aPBLG (Figure 1). In the current research, the molecular weight of PEG block was 5 kDa, and the degree of polymerization of the PBLG was 50. The synthesis was accomplished in a step order as depicted in Figure 2A. The 1H NMR spectra of PEG-b-PBLG50 is depicted in Figure 2B, and the characteristic proton peaks of both PEG and PBLG block were in existence, corroborating that the synthesis proceeded in a controlled way and was successful. The gel permeation chromatograms (GPCs) of PEG-b-PBLG are depicted in Figure 3 and the GPCs showed a sharp unimodal GPC peak, and the molecular weight of the termination product PEG-b-PBLG50 gained from the GPC detection is listed in Table 1. The FT-IR of PEG-b-PBLG50 is depicted in Figure 3D and the FT-IR showed that the absorption peaks at 1,734 and 1,167 cm−1 were the ester linkage of PEG-b-PBLG50 and the characteristic peaks at 1,652 and 1,547 cm−1 were acid amides I and II, affirming that the synthesis proceeded successfully.
The evaluation of cell toxicity from PEG-b-PBLG50 on EC9706 cells was checked in 24-h culturing and the result is revealed in Figure 3B. The PEG-b-PBLG50 showed low cell toxicity even below a concentration as high as 300 μg/mL.
Simvastatin could be efficiently loaded through PEG-b-PBLG50 at physiological pH by the hydrophobic interaction. Simvastatin was added to PEG-b-PBLG50 (mass ratio, 1:5) and dialyzed (MWCO, 7 kDa) against PB solution (pH 7.4, 0.01 mmol/L). The dialysis of free simvastatin as a control was also conducted at the same condition in a PB solution. To decide the load of simvastatin in PEG-b-PBLG50, the quantity of simvastatin was checked by HPLC in the dialysate and deducted from the total quantity of added simvastatin. The load of simvastatin was 41.8% by calculating, expressed as the mass ratio of loaded simvastatin to the polymeric compound host (Table 1).
The simvastatin release from PEG-b-PBLG50 was measured by dialysis (MWCO, 7 kDa) under room temperature, with 5 mL of simvastatin/PEG-b-PBLG50 against a PB solution of 0.02 mol/L (pH of 7.4). The release curve of simvastatin/PEG-b-PBLG50 is depicted in Figure 3C. After 2 h, ~48.94% of the simvastatin was released from simvastatin/PEG-b-PBLG50, manifesting the beginning of a burst release of simvastatin. Approximately 67.72% of the simvastatin was released after 2 days and ~97% after 4 days, manifesting biphase release profile from simvastatin/PEG-b-PBLG50.
It is shown in Figure 3D. The concentration of simvastatin in the plasma of SD rats following a single subcutaneous injection in Sim group at a dose of 20 mg/kg rapidly reached Cmax of 163.56 ng/mL at a Tmax of 2 h, and declined to baseline values within 10 h of administration. The plasma concentration of SD rats following a single subcutaneous injection in Sim/P group at a dose of 20 mg/kg reached Cmax of 41.25 ng/mL at a Tmax of 2 h, and declined to baseline values within 4 days of administration. These results showed that the release of simvastatin from Sim/P group was substantially sustained compared to Sim group.
It is depicted in Figure 4. The disintegrations per minute (DPM) of spleen was maximum and then was kidney and heart. However, the DPM of intestine, lung, and liver was minimum. This showed that a part of simvastatin from simvastatin/PEG-b-PBLG50 compound was swallowed by the phagocyte of spleen, but was not swallowed by the phagocyte of liver, then a part of simvastatin from simvastatin/PEG-b-PBLG50 compound accumulated in the kidney, heart, intestine, and so on. The result showed that simvastatin-loaded PEG-b-PBLG50 could avoid liver metabolism.
As shown in Figure 5A and B, SOD activity in intestinal tissue in I/R group rats was less than that in the Sham group (P<0.01). SOD activity in intestinal tissue reached 156.78±1.24 U in Sham group, whereas SOD activity in intestinal tissue in I/R group reached 105.63±2.78 U. Administration of simvastatin increased SOD activity (128.96±1.05 U) in intestinal tissues, compared with SOD activity in intestinal tissues in the I/R group rats (P<0.01). Administration of simvastatin/PEG-b-PBLG50 remarkably increased SOD activity (139.03±1.23 U), which was remarkably higher than that in the I/R group (P<0.01); MDA level in intestinal tissue in I/R group rats was greater than in Sham group (P<0.01). MDA content in intestinal tissue reached 0.33±0.08 nmol in Sham group, whereas MDA content in intestinal tissue in I/R group reached 0.71±0.02 nmol. Administration of simvastatin decreased MDA content (0.51±0.06 nmol) in intestinal tissue, compared with the MDA content in intestinal tissue in the I/R group rats (P<0.01). Administration of simvastatin/PEG-b-PBLG50 remarkably decreased MDA content (0.42±0.04 nmol), which was remarkably lower than that in the I/R group (P<0.01).
As shown in Figure 5C, IL-4 content in serum in I/R group rats was higher than that in the Sham group (P<0.01). IL-4 content in serum reached 4.19±0.38 ng in Sham group, whereas IL-4 content in serum in I/R group reached 15.27±0.71 ng. Administration of simvastatin decreased IL-4 content (11.32±0.59 ng) in serum, compared with the IL-4 content in serum in the I/R group rats (P<0.01). Administration of simvastatin/PEG-b-PBLG50 remarkably decreased IL-4 content (8.08±0.95 ng), which was remarkably lower than that in the I/R group (P<0.01); IL-6 content in serum in I/R group rats was greater than that in the Sham group (P<0.01). IL-6 level in serum reached 19.36±1.01 ng in Sham group, whereas IL-6 content in serum in I/R group reached 50.03±1.22 ng. Administration of simvastatin decreased IL-6 content (39.85±0.98 ng) in serum, compared with IL-6 content in serum in I/R group rats (P<0.01). Administration of simvastatin/PEG-b-PBLG50 remarkably decreased IL-6 level (28.96±1.15 ng), which was remarkably lower than that in the I/R group (P<0.01); IL-10 content in serum in I/R group rats was greater than that in the Sham group (P<0.01). IL-10 content in serum reached 14.65±1.23 ng in Sham group, whereas IL-10 content in serum in I/R group reached 47.53±2.21 ng. Administration of simvastatin increased IL-6 level (60.03±2.76 ng) in serum, compared with 1L-10 content in serum in the I/R group rats (P<0.01). Administration of simvastatin/PEG-b-PBLG50 remarkably increased IL-10 content (78.85±3.01 ng), which was remarkably greater than that in the I/R group (P<0.01); TNF-α content in serum in I/R group rats was greater than that in the Sham group (P<0.01). TNF-α content in serum reached 16.74±1.32 ng in Sham group, whereas TNF-α content in serum in I/R group reached 89.23±2.88 ng. Administration of simvastatin decreased TNF-α content (70.66±1.78 ng) in serum, compared with TNF-α content in serum in I/R group rats (P<0.01). Administration of simvastatin/PEG-b-PBLG50 remarkably decreased TNF-α content (54.15±1.36 ng), which was remarkably lower than that in I/R group (P<0.01).
As shown in Figure 5D and E, NO2−/NO3− content in serum in I/R group rats was lower than that in the Sham group (P<0.01). NO2−/NO3− content in serum reached 24.27±1.08 μmol in Sham group, whereas NO2−/NO3− content in serum in I/R group reached 7.8±1.11 μmol. Administration of simvastatin increased NO2−/NO3− content (9.1±0.87 μmol) in serum, compared with NO2−/NO3− content in serum in I/R group rats (P<0.01). Administration of simvastatin/PEG-b-PBLG50 remarkably increased NO2−/NO3− content (12.3±0.65 μmol), which was remarkably greater than that in the I/R group (P<0.01); the dry/wet (D/W) intestine ratios in I/R groups rats were lower than those in Sham group (P<0.01). The D/W intestine ratios reached 3.08±0.06 in Sham group, whereas the D/W intestine ratios in I/R groups reached 6.25±0.09. Administration of simvastatin increased the D/W intestine ratios (5.17±0.08) compared with the D/W intestine ratios in I/R group rats (P<0.01), whereas administration of simvastatin/PEG-b-PBLG50 remarkably increased the D/W intestine ratios (4.46±0.10), which were remarkably higher than those in I/R group (P<0.01).
Fluorescence microscopy images of intestine parts are shown in Figure 6. CM-H2DCFDA-positive cells were absent in intestinal tissue parts from Sham group. I/R group augmented mitochondrial ROS production, as affirmed through significant epithelial cell staining (CM-H2DCFDA fluorescence) of intestine tissue parts. Sim/P group significantly reduced ROS production, compared with production of ROS in I/R group.
eNOS, p47phox, p38MAPK, BMP4, and COX-2 expressions in intestinal tissues were checked by Western blot following the previously published method.21,38–40 The qualitative and quantitative outcomes are evaluated in Figure 7. The eNOS expressions in intestinal tissue in I/R group were greater than those in Sham group (P<0.01). Administration of simvastatin upregulated the eNOS expressions in intestinal tissue, compared with eNOS expressions by I/R group (P<0.01). Administration of simvastatin/PEG-b-PBLG50 remarkably upregulated eNOS expressions, compared with those in I/R group (P<0.01).
The p47phox, p38MAPK, BMP4, and COX-2 expressions in intestinal tissue in I/R group were greater than those in Sham group (P<0.01). Administration of simvastatin downregulated p47phox, p38MAPK, BMP4, and COX-2 expressions in intestinal tissue, compared with p47phox, p38MAPK, BMP4, and COX-2 expressions in I/R groups (P<0.01). Administration of simvastatin/PEG-b-PBLG50 remarkably downregulated p47phox, p38MAPK, BMP4, and COX-2 expressions, compared with those in I/R group (P<0.01).
As shown in Figure 8, expressions of COX-2, BMP4, and p38MAPK in intestinal tissues that were induced by I/R are greater than those in Sham group. Administration of simvastatin downregulated COX-2, BMP4, and p38MAPK expressions in intestinal tissue, compared with COX-2, BMP4, and p38MAPK expressions in intestinal tissue by induced I/R group, whereas administration of simvastatin/PEG-b-PBLG50 downregulated COX-2, BMP4, and p38MAPK expressions, which were remarkably lower than in the I/R group.
This is the first research to reveal that simvastatin and simvastatin/PEG-b-PBLG50 pretreatment can both weaken intestine injury induced by intestinal I/R. We discovered that intestinal inflammatory reaction is remarkably mitigated after simvastatin and simvastatin/PEG-b-PBLG50 preconditioning. The protective action is partially downregulated with BMP4 and COX-2, manifesting that the underlying mechanisms are associated with either BMP4 and COX-2-dependent or -independent pathways.
The intestinal mucosal injury is a major factor contributing to the pernicious complications of intestinal II/RI.44 It is a well-known phenomenon that ROS-induced lipid peroxidation, proinflammatory and anti-inflammatory imbalance, and disorder of nitroso-redox balance lead to intestinal injury.12,22,45 Previous documents have also demonstrated that powerful oxidative stress starting in the epithelium upon recovery of blood cell circulations is a primary reason of necrosis of the intestinal epithelium on I/R-induced injury.46 In the present study, we demonstrate that simvastatin and simvastatin/PEG-b-PBLG50 pretreatment ameliorate oxidative stress damage, bate inflammatory response, and restore nitroso-redox balance (Figures 5, ,6,6, and and7A7A).
In the study, we find that on II/RI rats, the protein contents and expression of BMP4 are augmented, and then p38MAPK and oxidative stress are activated, leading to upregulation of COX-2 protein levels and expression, where the pathway contributes to augmentation of II/RI. Simvastatin and simvastatin/PEG-b-PBLG50 interestingly reverse the activation of the above pathway (Scheme 1). This also shows that BMP4 can enhance NADPH oxidase to promote NADPH oxidase subtype (including p47phox) expression, resulting in COX-2 expression upregulation through p38MAPK-dependent mechanism in our research. In our study, we found that simvastatin and simvastatin/PEG-b-PBLG50 attenuate BMP4, COX-2, p47phox, p38MAPK, and ROS expression. All of the above experimental results attest that BMP4/ROS/p38MAPK/COX-2 pathway is involved in II/RI. These results are in agreement with other documents.21 To sum up, our present research reveals that simvastatin and simvastatin/PEG-b-PBLG50 preconditioning can provide intestine protection after II/RI through downregulating BMP4/COX-2 pathway, whereas simvastatin/PEG-b-PBLG50 significantly improves the effect.
In addition, there are some limitations in our research. In our tests, the HE staining is not measured owing to the limited number of mice. On the other hand, we only found the association between simvastatin and simvastatin/PEG-b-PBLG50 and the BMP4/ROS/p38MAPK/COX-2 pathway. The exact mechanism of how simvastatin and simvastatin/PEG-b-PBLG regulate the above pathway needs to be further explored.
The synthesized PEG-b-PBLG50 can evidently enhance the bioactivity of simvastatin, and the distribution experiment shows that simvastatin/PEG-b-PBLG50 can escape liver phagocytosis to improve the circulation time of simvastatin in vivo. The observational protective effect can be due to the antioxidative stress, anti-inflammatory properties, and the regulation of BMP4/COX-2 pathway by simvastatin/PEG-b-PBLG50 in rats as compared to free simvastatin. Further detailed research is required to probe the underlying mechanisms of simvastatin/PEG-b-PBLG50 on II/RI in rats.
This study was financially supported by the Department of Education, Zhejiang Government under Key Research Program.
All authors contributed toward data analysis, drafting and critically revising the paper, gave final approval of the version to be published, and agree to be accountable for all aspects of the work.
The authors report no conflicts of interest in this work.